← The Wire
BMRNNasdaq
BIOMARIN PHARMACEUTICAL INC
Pharmaceutical Preparations · DE · CIK 1048477
BioMarin develops and commercializes medicines for people with genetically defined rare diseases
red 8-K · 90d
$10.81B
Market cap
$57.67
Last close
-2.3%
1D
+3.2%
5D
1.8M
Volume
Price · last 39 sessions+4.0%
May 4L $49.67 · H $59.00Jun 29
172
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 4, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 4, 20268-KMaterial Agreement · Acquisition / DispositionApr 27, 20268-KCompany UpdateApr 23, 2026DEFA14ADEFA14AApr 21, 2026DEF 14ADEF 14AApr 21, 20268-KCompany UpdateMar 16, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 23, 20268-KMaterial Agreement · New Debt / ObligationFeb 12, 20268-KReg FD DisclosureJan 29, 20268-KResults of Operations · Reg FD DisclosureJan 26, 20268-KResults of OperationsJan 12, 20268-KCompany UpdateDec 22, 20258-KMaterial Agreement · Reg FD DisclosureDec 19, 20258-KExecutive ChangeDec 17, 202510-Q10-QOct 28, 20258-KResults of OperationsOct 27, 20258-KResults of OperationsOct 7, 20258-KExecutive ChangeAug 11, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 4, 20258-KExecutive ChangeAug 1, 20258-KExecutive Change · Shareholder VoteMay 22, 20258-KMaterial Agreement · Reg FD DisclosureMay 16, 202510-Q10-QMay 2, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AApr 8, 2025DEF 14ADEF 14AApr 8, 20258-KSecurity-Holder Rights · Bylaw AmendmentMar 3, 20258-KExecutive ChangeFeb 24, 202510-K10-KFeb 24, 20258-KResults of OperationsFeb 19, 202510-Q10-QOct 31, 20248-KResults of OperationsOct 29, 2024SC 13GSC 13GSep 30, 20248-KReg FD DisclosureSep 24, 20248-KMaterial Agreement · New Debt / ObligationSep 4, 20248-KExit / Disposal CostsAug 28, 20248-KExecutive ChangeAug 22, 202410-Q10-QAug 5, 20248-KResults of OperationsAug 5, 20248-KShareholder VoteMay 24, 20248-KExit / Disposal CostsMay 14, 202410-Q10-QApr 26, 20248-KResults of OperationsApr 24, 20248-KCompany UpdateApr 23, 2024DEFA14ADEFA14AApr 9, 2024DEF 14ADEF 14AApr 9, 202410-K10-KFeb 26, 20248-KResults of OperationsFeb 22, 2024SC 13GSEC SCHEDULE 13GFeb 9, 20248-KExecutive ChangeJan 11, 20248-KExecutive Change · Material AgreementDec 20, 20238-KExecutive ChangeNov 3, 202310-Q10-QNov 2, 20238-KResults of OperationsNov 1, 202310-Q10-QAug 2, 20238-KResults of OperationsJul 31, 20238-KExecutive Change · Shareholder VoteMay 30, 202310-Q10-QApr 28, 20238-KResults of OperationsApr 26, 2023DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 11, 2023DEF 14ADEFINITIVE PROXY STATEMENTApr 11, 202310-K10-KFeb 27, 20238-KResults of OperationsFeb 27, 20238-KResults of OperationsJan 11, 20238-KBylaw AmendmentDec 21, 202210-Q10-QOct 28, 20228-KResults of OperationsOct 26, 20228-KExit / Disposal CostsOct 7, 20228-KReg FD DisclosureSep 12, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 3, 20228-KShareholder VoteMay 31, 20228-KExecutive ChangeMay 5, 202210-Q10-QApr 29, 20228-KResults of OperationsApr 27, 2022DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 12, 2022
Insider Activity
In the 90 days to Mar 11, 2026: 3 sold $3.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2026 | Guyer Charles GregEVP, Chief Technical Officer | Sell | 16,486 | $60.46 | $997K |
| Feb 26, 2026 | Davis George EricEVP, Chief Legal Officer | Sell | 26,061 | $61.36 | $1.6M |
| Feb 26, 2026 | Friberg Gregory REVP, Chief R&D Officer | Sell | 6,326 | $60.38 | $382K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance